Psyence Financial Statements From 2010 to 2026

PBM Stock  USD 0.72  0.05  6.49%   
Psyence Biomedical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Psyence Biomedical's valuation are provided below:
Market Capitalization
787.1 K
Earnings Share
(62.40)
There are over ninety-nine available trending fundamental ratios for Psyence Biomedical, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to check out Psyence Biomedical's recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 29th of January 2026, Market Cap is likely to drop to about 2.6 M. In addition to that, Enterprise Value is likely to grow to about (4.1 M)
Check Psyence Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Psyence Biomedical's main balance sheet or income statement drivers, such as Net Interest Income of 104.5 K, Interest Income of 115.7 K or Selling General Administrative of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.39. Psyence financial statements analysis is a perfect complement when working with Psyence Biomedical Valuation or Volatility modules.
  
Build AI portfolio with Psyence Stock
Check out the analysis of Psyence Biomedical Correlation against competitors.

Psyence Biomedical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.3 M6.6 M34.7 M
Pretty Stable
Other Current Liabilities363.2 K382.3 K889.8 K
Pretty Stable
Total Current Liabilities649.3 K683.5 K1.7 M
Slightly volatile
Accounts Payable550.6 K301.2 K205.2 K
Slightly volatile
Cash7.4 M7.1 M4.4 M
Very volatile
Cash And Short Term Investments7.4 M7.1 M4.4 M
Very volatile
Net Receivables91.9 K157.9 K120.5 K
Slightly volatile
Common Stock Shares Outstanding485.7 K511.2 K12.6 M
Pretty Stable
Liabilities And Stockholders Equity6.3 M6.6 M34.7 M
Pretty Stable
Other Current Assets465 K330.9 K176.7 K
Slightly volatile
Total Liabilities508.2 K534.9 K2.9 M
Slightly volatile
Total Current Assets7.9 M7.5 M4.7 M
Very volatile
Common Stock52.8 M55.6 M207.9 M
Slightly volatile
Short and Long Term Debt Total6.1 M12 M2.8 M
Slightly volatile
Capital Stock41.7 M71 M17.5 M
Slightly volatile
Short Term Debt6.1 M12 M2.8 M
Slightly volatile
Short and Long Term Debt8.4 M9.4 M10.3 M
Slightly volatile
Accumulated Other Comprehensive Income284.9 K316.1 K353.4 K
Slightly volatile

Psyence Biomedical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.3 M3.8 MM
Slightly volatile
Selling And Marketing Expenses97.3 K92.7 K33.4 K
Slightly volatile
Other Operating Expenses2.2 M4.2 M1.1 M
Slightly volatile
Research Development608.6 K308 K321.7 K
Slightly volatile
Total Operating Expenses2.2 M4.2 M1.1 M
Slightly volatile
Depreciation And Amortization2.5 K4.9 K883
Slightly volatile
Cost Of Revenue2.5 K4.9 K883
Slightly volatile

Psyence Biomedical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow626.9 K659.9 K3.6 M
Slightly volatile
End Period Cash Flow7.4 M7.1 M1.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables858 K474 K803.6 K
Slightly volatile
Capex To Depreciation2.532.6620.0929
Slightly volatile
Payables Turnover0.01540.01470.0031
Slightly volatile
Cash Per Share10.219.721.8288
Slightly volatile
Days Payables Outstanding24.5 K25.8 K708.6 K
Slightly volatile
ROE0.130.140.3255
Slightly volatile
Current Ratio15.6912.6934.3915
Slightly volatile
Graham Number20.5819.69.8262
Slightly volatile
Capex Per Share0.01640.01560.0036
Slightly volatile
Average Receivables56.3 K80.6 K55.6 K
Slightly volatile
Interest Debt Per Share0.01780.01880.1139
Pretty Stable
Debt To Assets8.728.312.0895
Slightly volatile
Days Of Payables Outstanding24.5 K25.8 K708.6 K
Slightly volatile
Quick Ratio15.8212.6934.433
Slightly volatile
Cash Ratio14.7111.8733.1657
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9841
Slightly volatile
Debt Ratio8.728.312.0895
Slightly volatile
Return On Equity0.130.140.3255
Slightly volatile

Psyence Biomedical Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 M2.7 M117.4 B
Slightly volatile

Psyence Fundamental Market Drivers

About Psyence Biomedical Financial Statements

Psyence Biomedical investors utilize fundamental indicators, such as revenue or net income, to predict how Psyence Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-506.1 K-531.4 K
Cost Of Revenue4.9 K2.5 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Psyence Biomedical is a strong investment it is important to analyze Psyence Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Psyence Biomedical's future performance. For an informed investment choice regarding Psyence Stock, refer to the following important reports:
Check out the analysis of Psyence Biomedical Correlation against competitors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Biotechnology sector continue expanding? Could Psyence diversify its offerings? Factors like these will boost the valuation of Psyence Biomedical. Anticipated expansion of Psyence directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Psyence Biomedical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(62.40)
Return On Assets
(0.34)
Return On Equity
(0.74)
Psyence Biomedical's market price often diverges from its book value, the accounting figure shown on Psyence's balance sheet. Smart investors calculate Psyence Biomedical's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Psyence Biomedical's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Psyence Biomedical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Psyence Biomedical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.